{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:14:48Z","timestamp":1783606488345,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.leukres.2026.108255","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:22:39Z","timestamp":1779319359000},"page":"108255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association of hypomethylating agents +\u202fvenetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7741-862X","authenticated-orcid":false,"given":"Roberto","family":"Latagliata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorela","family":"Lame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alda","family":"Strazimiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Cavalca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Zoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Niscola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-8121","authenticated-orcid":false,"given":"Raffaele","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Esposito","family":"Vangone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-8186","authenticated-orcid":false,"given":"Michelina","family":"Santopietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-2621","authenticated-orcid":false,"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Di Veroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-158X","authenticated-orcid":false,"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ciuffreda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Renzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prassede","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-5412","authenticated-orcid":false,"given":"Elena Maria","family":"Elli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Poloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.leukres.2026.108255_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2022.101379","article-title":"Accelerated and blast phase myeloproliferative neoplasms","volume":"35","author":"Saliba","year":"2022","journal-title":"Best Pract. Res Clin. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2026.108255_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108255_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.ircmb.2021.02.008","article-title":"Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN","volume":"366","author":"Pasca","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108255_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjh.19010","article-title":"Updates on accelerated and blast phase myeloproliferative neoplasms: are we making progress?","volume":"203","author":"Mahdi","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108255_bib5","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression in Philadelphia-negative myeloproliferative neoplasms to myelodisplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on behalf og Groupe Francophone del Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108255_bib6","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2026.108255_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hon.2635","article-title":"Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated\/blastic phase with azacytidine. Clinical results and identification of prognostic factors","volume":"37","author":"Andriani","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108255_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/07853890.2022.2164611","article-title":"Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis","volume":"55","author":"Chen","year":"2023","journal-title":"Ann. Med."},{"issue":"4","key":"10.1016\/j.leukres.2026.108255_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.26849","article-title":"Blast phase myeloproliferative neoplasm: transplant to the rescue","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108255_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-023-00878-8","article-title":"Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm","volume":"13","author":"Tefferi","year":"2023","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.leukres.2026.108255_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2026.108255_bib12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108255_bib13","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","article-title":"Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs","volume":"5","author":"Masarova","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2026.108255_bib14","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/ajh.26381","article-title":"Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms","volume":"97","author":"King","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108255_bib15","first-page":"9675","article-title":"Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm","volume":"140","author":"Gangat","year":"2022","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.leukres.2026.108255_bib16","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/bloodadvances.2024012880","article-title":"Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era","volume":"8","author":"Patel","year":"2024","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.leukres.2026.108255_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70202","article-title":"Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination\u2013a FIM study","volume":"9","author":"Orvain","year":"2025","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.leukres.2026.108255_bib18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.leukres.2026.108255_bib19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.leukres.2012.08.013","article-title":"Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium","volume":"36","author":"Mascarenhas","year":"2012","journal-title":"Leuk. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2026.108255_bib20","doi-asserted-by":"crossref","first-page":"S1025","DOI":"10.1182\/blood-2025-1025","article-title":"Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): results of ENABLE, a GIMEMA and AIRC-Mynerva multicenter, Phase 2 trial","volume":"146","author":"Vannucchi","year":"2025","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2026.108255_bib21","doi-asserted-by":"crossref","first-page":"S3751","DOI":"10.1182\/blood-2025-3751","article-title":"Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine","volume":"146","author":"Guglielmelli","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108255_bib22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.20187","article-title":"Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status","volume":"207","author":"Badar","year":"2025","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108255_bib23","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood-2017-03-772939","volume":"130","author":"Drummond","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108255_bib24","article-title":"Efficacy of combined ruxolitinib and decitabine in patients with accelerated and blast-phase myeloproliferative neoplasms: results of a phase II study (MPN-RC 109 trial)","volume":"132","author":"Rampal","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108255_bib25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bjh.18853","article-title":"Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms","volume":"202","author":"Systchenko","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.leukres.2026.108255_bib26","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.leukres.2026.108255_bib27","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1111\/bjh.19027","article-title":"IDH1\/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: a multicentre experience","volume":"203","author":"Gangat","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108255_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100089","article-title":"Response and outcomes of patients with IDH1\/2- mutated accelerated\/blast-phase myeloproliferative neoplasms","volume":"2","author":"Goldberg","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"4","key":"10.1016\/j.leukres.2026.108255_bib29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3324\/haematol.2023.283950","article-title":"Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia","volume":"110","author":"Patel","year":"2025","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:22:16Z","timestamp":1783603336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"alternative-id":["S0145212626000998"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108255","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of hypomethylating agents +\u202fvenetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108255"}}